As of the most recent check today, Predictive Oncology Inc. (NASDAQ: POAI) shares were significantly rising 69.58% to $1.89. A notable advancement in creating a new compound in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan drove that momentum.
A Successful Collaboration with the University of Michigan
Predictive Oncology has partnered with the NPDC at the Life Sciences Institute at the University of Michigan to advance drug discovery. Applying Predictive’s state-of-the-art machine learning technology, which has proven successful in predicting the efficacy of possible drugs, is the main goal of the collaboration. To expedite the screening procedure and improve the likelihood of success, this platform makes use of a sizable biobank of live-cell tumor samples.
Novel Approaches to Cancer Treatment Using Natural Products
The NPDC has one of the largest natural products libraries in the United States, including specimens from biodiversity hotspots across the globe. Numerous authorized small-molecule medications have been generated from natural chemicals, which have historically played a significant role in drug development.
Three of the 21 new chemicals that Predictive Oncology evaluated showed consistently robust anti-tumor responses across a variety of cancer types, surpassing the effectiveness of the well-known chemotherapeutic medication doxorubicin.
Machine Learning to Speed Up Drug Discovery
Promising results were obtained by evaluating these chemicals on models of ovarian, colon, and breast cancer. Using only 7% of the potential wet lab experiments, POAI’s machine learning model successfully predicted outcomes for 73% of all possible tests. This significant reduction in experimental time could potentially eliminate up to two years of traditional lab testing.
Future Prospects and Further Investigations
By examining only 1% of the NPDC’s accessible chemicals, the partnership produced encouraging results that open the door for more research. The NPDC anticipates growing their collaboration with Predictive Oncology (POAI), investigating other substances, and disseminating the results of these continuing investigations.